Amy H Tang
Overview
Explore the profile of Amy H Tang including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
29
Citations
654
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bell J, Mayfield C, Collon K, Chang S, Gallo M, Lechtholz-Zey E, et al.
J Biomed Mater Res A
. 2024 Apr;
112(10):1688-1698.
PMID: 38602243
When delivering cells on a scaffold to treat a bone defect, the cell seeding technique determines the number and distribution of cells within a scaffold, however the optimal technique has...
2.
Bell J, Collon K, Mayfield C, Gallo M, Chang S, Sugiyama O, et al.
Gene Ther
. 2023 Aug;
30(12):826-834.
PMID: 37568039
Ex-vivo gene therapy has been shown to be an effective method for treating bone defects in pre-clinical models. As gene therapy is explored as a potential treatment option in humans,...
3.
Tang A, Hoefer R, Guye M, Bear H
Cancer Drug Resist
. 2022 Sep;
5(3):691-702.
PMID: 36176751
Triple-negative breast cancer (TNBC) is the most aggressive breast cancer subtype. It disproportionately affects BRCA mutation carriers and young women, especially African American (AA) women. Chemoresistant TNBC is a heterogeneous...
4.
Gits H, Tang A, Harmsen W, Bamlet W, Graham R, Petersen G, et al.
J Gastrointest Oncol
. 2021 Nov;
12(5):2275-2286.
PMID: 34790392
Background: Previous reports suggest that intact SMAD4 expression is associated with a locally aggressive pancreas cancer phenotype. The objectives of this work were to determine the frequency of intact SMAD4...
5.
Gupta G, Collier A, Lee D, Hoefer R, Zheleva V, van Reesema L, et al.
Cancers (Basel)
. 2020 Aug;
12(9).
PMID: 32846967
Triple-negative breast cancer (TNBC), characterized by the absence or low expression of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor (HER2), is the most aggressive subtype...
6.
Vakhshori V, Bougioukli S, Sugiyama O, Kang H, Tang A, Park S, et al.
Bone
. 2020 Jul;
138:115524.
PMID: 32622870
Background: The treatment of complex bone loss scenarios remains challenging. This study evaluates the efficacy of ex vivo regional gene therapy using transduced human adipose-derived stem cells (ASCs) overexpressing bone...
7.
Gupta G, Lee C, Guye M, Van Sciver R, Lee M, Lafever A, et al.
Ann Breast Cancer Ther
. 2020 Jun;
4(1):48-57.
PMID: 32542231
Chemo-resistant breast cancer is a major barrier to curative treatment for a significant number of women with breast cancer. Neoadjuvant chemotherapy (NACT) is standard first- line treatment for most women...
8.
Bougioukli S, Saitta B, Sugiyama O, Tang A, Elphingstone J, Evseenko D, et al.
Hum Gene Ther
. 2019 Feb;
30(7):906-917.
PMID: 30773946
Umbilical cord blood (UCB) has been increasingly explored as an alternative source of stem cells for use in regenerative medicine due to several advantages over other stem-cell sources, including the...
9.
White K, Swier V, Cain J, Kohlmeyer J, Meyerholz D, Tanas M, et al.
JCI Insight
. 2018 Jun;
3(12).
PMID: 29925695
Loss of the NF1 tumor suppressor gene causes the autosomal dominant condition, neurofibromatosis type 1 (NF1). Children and adults with NF1 suffer from pathologies including benign and malignant tumors to...
10.
Van Sciver R, Lee M, Lee C, Lafever A, Svyatova E, Kanda K, et al.
Cancers (Basel)
. 2018 May;
10(5).
PMID: 29757973
Oncogenic K-RAS mutations are found in virtually all pancreatic cancers, making K-RAS one of the most targeted oncoproteins for drug development in cancer therapies. Despite intense research efforts over the...